A Randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia

被引：29

作者：

Ledson, MJ ^{[1
]}

Gallagher, MJ ^{[1
]}

Robinson, M ^{[1
]}

Cowperthwaite, C ^{[1
]}

Williets, T ^{[1
]}

Hart, CA ^{[1
]}

Walshaw, MJ ^{[1
]}

机构：

[1] Univ Liverpool, Ctr Cardiothorac, Reg Adult Cyst Fibrosis Unit, Liverpool L14 3PE, Merseyside, England

来源：

JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG | 2002年 / 15卷 / 01期

关键词：

inhaled antibacterial agents; resistant pathogens;

D O I：

10.1089/08942680252908575

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Burkholderia cepacia is an aggressive pathogen that colonizes cystic fibrosis (CF) patients, causing greatly increased morbidity and mortality. It is resistant to most antibiotics, but sensitive in vitro to a novel agent, taurolidine. This has not previously been used against B. cepacia, nor given in nebulized form. We assessed the effect of nebulized taurolidine on United Kingdom epidemic (ET12) B. cepacia infection in 20 adult CF patients attending our regional adult cystic fibrosis outpatient clinic using a prospective, randomized, double-blinded placebo-controlled crossover trial. Nebulized taurolidine (4 mL 2% solution) or saline (4 mL 0.9% solution) was given twice daily. Each arm lasted 4 weeks, with a 2-week intervening washout period. Sputum B. cepacia colony counts (primary outcome measure), spirometry, and symptoms (secondary outcome measures) were assessed. Eighteen patients completed the study. There was no change in B. cepacia colony counts or spirometry, nor symptom scores. We conclude that, although taurolidine is well tolerated in nebulized form, in this study it had no in vivo anti-B. cepacia activity.

引用

页码：51 / 57

页数：7